Mioko Matsuo

Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda et al. · Oral Oncology · 2019 · 91 citations · Full text

Medicine, Immunology, Immune Checkpoint Inhibitor +10

Monitoring the neutrophil‐to‐lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer

Ryuji Yasumatsu, Takahiro Wakasaki, Kazuki Hashimoto et al. · Head & Neck · 2019 · 58 citations

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Ryutaro Uchi et al. · Auris Nasus Larynx · 2019 · 41 citations

Nivolumab Treatment, Neoadjuvant Therapy, Medicine +6

Small Cell Carcinoma in the Head and Neck

Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda et al. · Annals of Otology Rhinology & Laryngology · 2019 · 34 citations

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda et al. · Cancers · 2020 · 32 citations · Full text